This content is only available in German.
Dieser Inhalt ist nur auf Deutsch verfügbar.

0900 712 712
(3.23 CHF / min. from the Swiss landline, possibly additionally 8 Rp. / min. in the waiting loop by network operator)
0900 712 713

(3.12 CHF / min. for calls from prepaid cell phones, possibly additionally 8 Rp. / min. in the waiting loop by network operator)



Sie haben bereits ein Konto?


Sie sind noch nicht registriert?

Hotline for child and youth emergencies

The Medgate Kids Line provides fast and simple medical advice when your child is unwell. The medical team from our partner Medgate is available by phone around the clock.


0900 712 712

(3.23 CHF / min. from the Swiss landline, possibly additionally 8 Rp. / min. by network operator)


0900 712 713

(3.13 CHF / min. for calls from prepaid cell phones, possibly additionally 8 Rp. / min. by network operator)

Please note: the Medgate Kids Line is currently offered in German.


Important Numbers

  • 144   Ambulance
  • 145   Tox Center (Poisoning)
  • 117   Police
  • 118   Fire Department

Kontakt Box

Pediatric Infectious Diseases and Vaccinology

Nicole Ritz's research focuses on enhancing current strategies to diagnose and prevent tuberculosis (TB) in children. This includes immunodiagnostic tests including interferon gamma release assays (IGRA), novel cytokine-based assays and other biomarkers for early detection of childhood TB. Her research interest also focuses on Bacille-Calmette-Guérin (BCG) vaccine the only currently licenced vaccine against TB, in particular on specific and non-specific immune response including adaptive and innate immunity.

Jan Bonhoeffer's research strives to improve child health by preventing infectious diseases and optimizing treatment through improved diagnostics. His focus is on generating best evidence for benefit-risk assessment of vaccines with a global network of partners and health care databases. He is also investigating strategies to optimize antibiotic use by improving the diagnosis of respiratory tract infections in children.

Ulrich Heininger's main research interest lies in the field of pertussis, a respiratory tract disease caused by the bacterium Bordetella pertussis. He and his national and international collaborators are focussing mainly on the epidemiology and prevention of pertussis by vaccination. Further, Ulrich Heininger is working on the general acceptance and impact of immunization per se amongst the public as well as health care workers.

Main research projects

Please note that not every project listed here was necessarily initiated by our group.

ANSORP - A multicenter, multinational serosurvey study for pertussis among children 10-18 years old in Asia

Study goal: This study aims to measure IgG anti-PT in Asian children aged 10-18 years. This will enable us to identify how many children have evidence of a recent pertussis infection defined by IgG anti-PT above 125 IU/mL and how many children are potentially susceptible to pertussis infection when exposed.


Collaborators - UKBB - Universitäts-Kinderspital beider Basel - Pädiatrie - Kinderheilkunde - Pediatrics - Pédiatrie - Seltene Krankheiten - Rare Diseases - Maladies Rares - Perinatal Zentrum - Perinatal Center - Centre Périnatal - Pseudocrupp - Impfungen Baby - Baby Vaccination - Vaccin Bebe
  • Timelines: Start: Q3 or 4/2013; Duration: 24 months
  • Financial support: SPMSD, Lyon, France

Epidemiology of Pertussis in Switzerland – Hospitalized Cases via SPSU (Swiss Pediatric Surveillance Unit)

  • Study goal: To monitor the effect of new pertussis immunization recommendations in Switzerland (adolescents, young adults, and pregnant women) on the epidemiology of pertussis in children. This will be done using assessment of hospitalizations due to pertussis in children (0-15 years of age) within the framework of the Swiss Pediatric Surveillance Unit (SPSU).
  • Collaborators: Co-prinicipal investigators: Ulrich Heininger (UKBB) and Jean-Luc Richard (BAG); Further collaborators: all Swiss pediatric hospitals and units (SPSU); Laboratory analyses: IMM; Univ. of Basel
  • Timelines: 01/2013 - 12/2016.
  • Financial support: BAG

The influence of host, laboratory and environmental factors on the performance of cytokine-based immunodiagnostic tests in children

PERISCOPE – PERtussIS COrrelates of Protection Europe

New Innovative Medicine Initiative (IMI) 2 project on the trail of next generation vaccines against pertussis (whooping cough) 

Despite the availability of effective prophylactic vaccines against pertussis, there has been a rise in the incidence of pertussis, with epidemics in Europe, Australia and the US in the last decade. As well as being a particular problem in vulnerable infants, with devastating consequences in developing countries, the incidence of pertussis is also increasing in adolescents and adults, particularly in industrialized countries. Hence, pertussis continues to be a major public health concern worldwide.

The pan-European initiative PERISCOPE sets out to accelerate improvement of prophylactic vaccines and vaccination strategies for pertussis. The project is funded with a total budget of €28mio over the next five years by the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Additionally, PERISCOPE is the first IMI project to receive funding from the Bill & Melinda Gates Foundation.

"Given the resurgence and changing epidemiology of pertussis in industrialized countries and the persistent low level of vaccination coverage and high infant mortality caused by pertussis in low income countries, PERISCOPE represents a concerted effort aiming to accelerate the development of improved vaccination strategies that ensure solid, long-lasting protection against infection", says Prof. Ronald de Groot from Radboud University Medical Center and coordinator of PERISCOPE. "This implies, first and foremost, that we need to gain a better understanding of the pathogenesis and underlying mechanisms of the infection to be able to identify novel vaccine candidates. However, it is equally important to rebuild the ecosystem for pertussis research and the technical infrastructure needed in Europe to successfully evaluate those novel candidates".

PERISCOPE will focus on three major areas:

1) Setting up a comprehensive clinical research programme to study the immune response of individuals of all ages to pertussis infection and vaccination; 2) the establishment of parallel clinical and pre-clinical models of pertussis infection, and 3) the development of a comprehensive battery of state-of-the-art bioassays, to help reveal  the markers of an effective and long-lasting immune response to pertussis infection in both clinical and preclinical study subjects. PERISCOPE will also seek to study immunization in pregnancy to gain a better understanding of the impact of maternal antibodies on the infant’s immune responses to pertussis.

In the frame of this ambitious project, Prof. Ulrich Heininger will lead workpackage 4 with the goal to facilitate interaction with experts from regulatory and public health agencies to ensure acceptance of novel and existing biomarkers and facilitate improved design of small-scale Phase II/III trials.

PERISCOPE assembles a multi-national team of leading experts from 22 partnering institutions with long-standing experience in pertussis research, clinical trials, bioinformatics, immunology and public health. The consortium also includes Sanofi Pasteur and GlaxoSmithKline, two of the world’s largest and most experienced vaccine manufacturers, as industrial partners.

Partners in PERISCOPE


  • GlaxoSmithKline
  • Q-Biologicals NV
  • Université libre de Bruxelles

Czech Republic

  • Mikrobiologicky USTAV - AVCR, V.V.I.


  • Turun Yliopisto


  • Commissariat à l’énergie atomique et aux energies alternatives
  • Institut Pasteur de Lille Fondation
  • Sanofi Pasteur SA

The Gambia

  • Medical Research Council


  • Eurice GmbH


  • Trinity College Dublin


  • Leids Universiteir Medisch Centrum
  • Radboud university medical center
  • Rijksinstituut voor Volksgezondheid en Milieu part of the Dutch State


  • Universidad de Salamanca


  • Universität Basel
  • Hospices Cantonaux CHUV


  • The Chancellor, Masters and Scholars of the University of Oxford
  • Department of Health (Public Health England)
  • Imperial College of Science Technology and Medicine
  • University of Bath
  • University of Southampton

Project details

Name: PERISCOPE – PERtussIS COrrelates of Protection Europe
Start date: 2016-03-01
Duration: 60 months
Budget: €28mio
Coordination: Stichting Katholieke Universiteit, Radboud university medical center



  • Radboud university medical center
  • Prof. Ronald de Groot
  • Email
  • Phone: +31 24 366 73 47

Project Management

  • Eurice - European Research and Project Office GmbH
  • Dr. Claudia Schacht
  • Email
  • Phone: +49 30 370 44 15 831

EFPIA Coordinator

  • Sanofi Pasteur
  • Dr. Patricia Londoño-Hayes

More information about the project

  • Epidemiology of tuberculosis in Swiss children
  • Improving the diagnosis of tuberculosis in children: combining cytokine-based immunodiagnosis with direct and indirect detection of Mycobacterium tuberculosis
  • Improving the reading of tuberculin skin tests

Only available in German


Group members

  • Chloé Schläppi, MD
  • Nina Vaezipour, MD
  • Rahel Erlacher, MD
  • Michael Büttcher, MD
You can also find us here
UKBB FacebookUKBB YoutubeUKBB LinkedInUKBB Instagram


0900 712 712

(3.23 CHF/min. CH-landline, possibly additionally 8 Rp. / min. by network operator)

0900 712 713

(3.12 CHF/min. prepaid cell phones, possibly additionally 8 Rp. / min. by network operator)

Site Map


University Children’s Hospital Basel
Spitalstrasse 33
4056 Basel / Switzerland

T +41 61 704 12 12




University Children’s Hospital Basel
Spitalstrasse 33
4056 Basel / Switzerland

T +41 61 704 12 12

© UKBB, 2024


Diese Website verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Website stimmen Sie der Verwendung von Cookies und ähnlichen Technologien zu. Weitere Informationen finden Sie in unserer Datenschutzerklärung.